The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cells

AIDS. 2009 Sep 24;23(15):2047-50. doi: 10.1097/QAD.0b013e328330342c.

Abstract

We investigated the ability of several novel class I histone deacetylase inhibitors to activate HIV-1 transcription in latently infected cell lines. Oxamflatin, metacept-1 and metacept-3 induced high levels of HIV-1 transcription in latently infected T cell and monocytic cells lines, were potent inhibitors of histone deacetylase activity and caused preferential cell death in transcriptionally active cells. Although these compounds had potent in-vitro activity, their cytotoxicity may limit their use in patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Death / drug effects
  • Cell Line
  • Drug Evaluation, Preclinical / methods
  • HIV-1 / drug effects*
  • HIV-1 / genetics
  • HIV-1 / physiology
  • Histone Deacetylase Inhibitors
  • Histone Deacetylases / metabolism
  • Humans
  • Hydroxamic Acids / pharmacology*
  • Sulfonamides / pharmacology*
  • T-Lymphocytes / virology*
  • Transcriptional Activation / drug effects*
  • Virus Latency / drug effects

Substances

  • Histone Deacetylase Inhibitors
  • Hydroxamic Acids
  • Sulfonamides
  • metacept-1
  • oxamflatin
  • Histone Deacetylases